Breakthrough Research On An Advanced Form Of MCP

In this segment, renowned integrative practitioner Dr. Isaac Eliaz announces breakthrough clinical research on an advanced new preparation of Modified Citrus Pectin (MCP) in the treatment of patients with advanced solid tumors.

In a recently published peer-reviewed German study, 49 patients with treatment-resistant advanced state cancers— including cancer of the colon, lung, breast, prostate, throat, pancreatic, and ovaries—were administered 15 grams of MCP per day for periods of varying length. Prior to this trial, all of the patients had previously undergone traditional surgery, radiation, and chemotherapy treatments and approximately 90 percent of the cancers had metastasized. At the end of the trial, the majority of the patients demonstrated a significant improvement in quality of life and pain measurements—including one advanced state prostate cancer patient who experienced a remarkable 50-percent decrease in PSA levels over the course of 16 weeks.

This trial is the first of its kind to implement a new, more advanced, and more effective preparation of MCP. Unlike previous forms of modified citrus pectin (with an average molecular weight of 12,000 Daltons and consisting of 18 to 20 percent monogalacturonic acid), this new form utilizes a cutting edge enzymatic process and drying technique to yield a stronger and more bioavailable product—achieving an ideal molecular weight of 7,000 to 8,000 Daltons, and consisting of only 5 percent free sugars. The implications of this innovation are groundbreaking. The results of this study implementing the new form MCP are equivalent to (if not better than) the results achieved in the same group of patients with chemotherapy—but without the side effects, and without the toxicity.

Consequently, while MCP may not replace conventional therapies, it has nevertheless revealed itself as an integral part of a whole program for patients with cancer.